Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Halozyme Therapeutics Inc HALO
$67.12
▼ -3.02%
($-2.09)
Open
$69.21
Prev Close
$69.21
Day Range
$66.31 – $69.66
52W Range
$47.74 – $82.22
Market Cap
$7.96B
P/E (TTM)
25.12
Beta
0.88
EPS (TTM)
$2.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2003-01-30 |
| Shares Out. | 118,470,000 |
| Website | halozyme.com/ ↗ |
| Phone | 13026587581 |
Halozyme Therapeutics Inc is a publicly traded company under the ticker symbol HALO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-05-01)
📰 Latest News for HALO
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
Halozyme Therapeutics Earnings: What To Look For From HALO
Company News for May 13, 2026
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley
Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $93